InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN), AffaMed Announce Substantial Progress Toward Initiating PALISADE Global Trial
VistaGen (NASDAQ: VTGN) and AffaMed Therapeutics have announced completion of regulatory preparations to initiate PALISADE Global, a phase 3 clinical trial to evaluate the efficacy, safety and tolerability of VistaGen’s PH94B (referred to by AffaMed as “AM005”) for the acute treatment of anxiety in adults with social anxiety disorder (“SAD”), in the U.S. and China. The primary purpose of PALISADE Global, based on VistaGen’s ongoing…